11 HURON DR STE 200, NATICK, MA
Advances Plan to Regain Listing Compliance
Intends to Appeal NYSE Notice of Delisting While Executing Plan to Regain Compliance and Expects to Remain Trading
Allurion Technologies Enters Warrant Exercise Inducement Agreement
Receives U.S. FDA Approval for the Gastric Balloon System, Featuring the Smart Capsule
Announces Preliminary Fourth Quarter and Full-Year 2025 Results
News
Annual Report to Security Holders
Reports Third Quarter 2025 Financial Results and Provides Business Update, Allurion Achieves FDA Milestones, Moves to Eliminate Debt with $5M Financing
FY 2025
Q3
Notice of Late Filing for Quarterly Report
Amended Annual Report
Amended Quarterly Report
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload